Sorrento Therapeutics, Inc.
DelistedCIK 850261fmd_1K2S4Q2ABT1BTXA8ZW5E3A4SMFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2007 to Jun 30, 2023, 56 periods
Latest annual · FY2022
Millions- Total revenues
- 63
- Gross profit
- 14
- Operating income
- (504)
- Net income
- (573)
- Free cash flow
- (308)
Latest quarter · Q2 FY2023
Millions- Total revenues
- 15
- Operating income
- (77)
- Net income
- (95)
- Free cash flow
- (56)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- +26.0%
- Revenue, 5 yearsFY2017 to FY2022
- -16.2%
- Net income, 5 yearsFY2017 to FY2022
- n/m
Sorrento Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $62.8 million | $52.9 million | +18.8% | 10-K 2023-03-16 · proof |
| Operating income | -$504.3 million | -$401.5 million | 10-K 2023-03-16 · proof | |
| Net income | -$572.8 million | -$428.3 million | 10-K 2023-03-16 · proof | |
| Cash from operating activities | -$293.9 million | -$281.8 million | 10-K 2023-03-16 · proof | |
| Free cash flow | -$307.5 million | -$290.7 million | 10-K 2023-03-16 · proof | |
| Total assets | $472.8 million | $694.8 million | -31.9% | 10-K 2023-03-16 · proof |
| Total liabilities | $494.5 million | $616.7 million | -19.8% | 10-K 2023-03-16 · proof |
| Cash and cash equivalents | $23.6 million | $36.7 million | -35.5% | 10-K 2023-03-16 · proof |
| Total debt | $35.4 million | $142.6 million | -75.2% | 10-K 2023-03-16 · proof |
- What was Sorrento Therapeutics, Inc.'s revenue in fiscal 2022?
- Sorrento Therapeutics, Inc. reported revenue of $62.8 million for fiscal 2022 (the year ended Dec 31, 2022), against $52.9 million the year before (+18.8%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Sorrento Therapeutics, Inc.'s operating income in fiscal 2022?
- Sorrento Therapeutics, Inc. reported operating income of -$504.3 million for fiscal 2022 (the year ended Dec 31, 2022), against -$401.5 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Sorrento Therapeutics, Inc.'s net income in fiscal 2022?
- Sorrento Therapeutics, Inc. reported net income of -$572.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$428.3 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Sorrento Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- Sorrento Therapeutics, Inc. reported cash from operating activities of -$293.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$281.8 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What was Sorrento Therapeutics, Inc.'s free cash flow in fiscal 2022?
- Sorrento Therapeutics, Inc. reported free cash flow of -$307.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$290.7 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Sorrento Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, Sorrento Therapeutics, Inc. reported total assets of $472.8 million, against $694.8 million a year earlier (-31.9%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Sorrento Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, Sorrento Therapeutics, Inc. reported total liabilities of $494.5 million, against $616.7 million a year earlier (-19.8%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What are Sorrento Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Sorrento Therapeutics, Inc. reported cash and cash equivalents of $23.6 million, against $36.7 million a year earlier (-35.5%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
- What is Sorrento Therapeutics, Inc.'s total debt?
- As of Dec 31, 2022, Sorrento Therapeutics, Inc. reported total debt of $35.4 million, against $142.6 million a year earlier (-75.2%). Source: the 10-K filed with the SEC on Mar 16, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:850261&period_type=annual&limit=5"Information only, not investment advice.